IL37 and type 2 diabetes mellitus: We suggest a model of phenotypes of older individuals with T2D that is based on clustering IL-37 and TSH as markers of the tissue level and system level of protective mechanisms that can compensate for inflammation-related organ damage and associated metabolic costs.